There are an increasing number of potential chemoprevention agents that need study. Beta carotene and a-tocopherol are currently being studied, usually in combination with a retinoid. The role of calcium and flavonoids will undoubtedly be the subject of clinical trials in the near future.26 Growth factors such as epidermal growth factor (EGF) and neuropeptides clearly play a role in the pathogenesis of many lung cancers.2'3 Growth factor antagonists CHEST / 106 / 6 / DECEMBER, 1994/ Supplement 399S
Even since the Surgeon General's 1964 report, the mortality rate from lung cancer has continued to rise. Although there is evidence that this continued increase in mortality will slow or level in the next decade, lung cancer mortality is a major health problem destined to remain with us for at least the next generation. There have been no established advances in the early detection or prevention of lung cancer in the last 30 Only a small minority of the cancers detected in this initial screen were detected by the sputum cytology examination alone. Thus, it is not too surprising that a reduction in lung cancer mortality was not detected in any of these studies despite the fact that there was more than the expected number of early cancers and the 5-year survival rate for the patients who had undergone resection was high.
Because of the deficiencies of these trials in evaluating the true value of annual chest radiographs as a screening test in high-risk individuals, the NCI is sponsoring a new trial that randomizes high-risk smokers to an annual chest radiograph or to no screening. This is part of a large national trial also looking at the role of other tests in the early detection of prostate, colorectal, and ovarian cancers. The study is referred to as the PLCO (prostate, lung, colorectal, ovarian) early detection trial.
The group from Johns Hopkins saved the sputum samples and follow-up cancer information on the patients from their study. When it became apparent that nearly all lung cancers have aberrant expression of several antigens and that monoclonal antibodies could be developed that recognize these antigens, the Hopkins group showed that ar- trials showed a significant survival advantage for the chemotherapy but others did not. In all of the trials, the patients treated with chemotherapy survived longer than those receiving only BSC, but often the differences were nonsignificant. All of these trials had less than 100 patients per arm and lacked the power to detect small increases in survival. Therefore, both literature-based and individual patient-based meta-analyses of the data from these trials have been performed.76 All of these meta-analyses showed significant survival advantages for the chemotherapy arms. Thus, it can be concluded that chemotherapy adds a small but significant survival advantage for these patients. It must be stressed that these trials were limited to patients with a good performance status (<2 Eastern Cooperative Oncology Group [ECOG] ) and that there is still no evidence that chemotherapy prolongs survival in patients with impaired performance status.
Unfortunately, there are no randomized trials that evaluated the quality of life in the respective groups. In fact, there are no standard validated tools for measuring the quality of life in these patients, although several have been proposed.77 A major limitation in these quality-of-life tools is the high rate of dropout due to tumor progression. These censored observations limit the power of the tools. Additional clinical trials in this area are needed and are in progress.
One of the randomized chemotherapy vs BSC trials, the Canadian NCI trial, assessed the costs associated with the treatments. The results of this analysis showed that treatment with CAP chemotherapy was associated with lower costs compared with BSC. 78 The explanation for the unexpected finding was that the patients treated with CAP chemotherapy spent less days in hospital and had less radiotherapy than patients on the BSC arm. This study also had a vindesine+cisplatin arm. The costs associated with this therapy were higher than the other two arms because patients required hospital admission for the cisplatin therapy. Patients receiving chemotherapy lived longer than those receiving BSC; when the costs per added year of life were calculated, they showed that the chemotherapy was more cost-effective than many standard medical procedures such as coronary surgery, transplants, or dialysis. With rising costs of medical care around the world, additional studies of this nature are clearly needed.
There has been considerable recent enthusiasm surrounding the discovery of new active agents in NSCLC, especially those with new mechanisms of action. Table 4 shows a list of the agents and the response rates reported and Figure 1 shows the survival results from one of these agents, paclitaxel (Taxol).49'50 Paclitaxel produced responses in 24% of the patients treated at the M.D. Anderson Cancer Center49 and 21% of the patients treated by the ECOG.50 While these response rates do not seem impressively high, it must be recalled that the most active drug, cisplatin, has a response rate of only 21% and the recently approved vinorelbine has a response rate of 14 to 33% 64, 65 The survival results of these two studies are more impressive than the response rates. As shown in Figure 1 , the 1-year survival rate was about 40% in both studies and the 2-year survival rates were about 28% and 18% in the two studies, respectively. This is higher than in nearly all combination studies. The excellent survival could be attributed solely to patient selection, but the ECOG study was a randomized phase 2 study with two other arms (piraxantrone and merbarone). The survival in these two arms of the study was not as good as the paclitaxel arm and closer to the expected survival of patients with stage IV disease. Future clinical trials will clearly need to evaluate paclitaxel in combination with other chemotherapeutic agents and in combination with radiotherapy. Initial paclitaxel studies administered the drug as a 24-h infusion. More recent studies in other cancers suggest that 3-h infusions are less myelosuppressive, more convenient, and equally effective as the 24-h infusions. The optimal dose and schedule of paclitaxel for lung cancer are unknown and need to be studied.
Docetaxel also appears to be active in NSCLC5'-3 and also requires further study alone and in combination with other agents to determine optimal dose, schedule, and combinations.
Another novel group of agents are the topoisomerase-1 inhibitors CPT-11, topotecan, and 9-aminocamptothecan.3'54 60 CPT-11 has been the most extensively studied.
As a single agent, it produced response rates of 29% in patients with NSCLC and 47% in patients with small cell lung cancer (SCLC). Phase 1 combination studies with cisplatin,56 etoposide,57 and cisplatin plus vindesine57 have shown promising response rates. The drug has been studied almost exclusively in Japan. Studies outside Japan, phase 2 combination studies, and eventually phase 3 studies will be necessary to determine the ultimate role of this agent. Topotecan has been studied in fewer patients and to my knowledge, there are no published combination studies, but it also appears to have considerable activity in patients with SCLC and lesser activity in patients with NSCLC.58 '60 It is likely that there is cross-resistance between these three topoisomerase-1 inhibitors but not with other active drugs or radiotherapy.
Initial studies with the antifol, 10 It is clinically obvious that lung cancers of all histologic types develop acquired drug resistance that often has the clinical features of "multidrug resistance" with resistance to anthracyclines, vinca alkaloids, and epipodophyllotoxins whether or not the patient was treated with these drugs. [84] [85] [86] [87] In some instances, the drug resistance was shown to be due to overexpression of the classic MDR-1 gene. In other instances, however, it is clear that the resistance is due to other mechanisms such as overexpression of the MRP protein or other proteins. Whether any modulator is capable of reversing or preventing multidrug resistance needs considerable investigation in lung cancer preclinical models and patients.
